Fecal Microbiota Transplant (FMT) for Gut Health: Evidence, Approvals, and What to Know

In Reno, Nevada, fecal microbiota transplant (FMT, also called a fecal transplant or stool transplant) is a specialist treatment for recurrent Clostridioides difficile (C. diff) infection, arranged through gastroenterologists and infectious disease physicians rather than wellness clinics. Two FDA approved fecal microbiota products, Rebyota (approved November 2022) and Vowst (approved April 2023), can be prescribed in Reno like any other drug, while FMT for IBS, Crohn’s disease or ulcerative colitis remains investigational and is best accessed through a registered clinical trial.

Fecal microbiota transplant has an image problem. The procedure sounds visceral, even repellent on first hearing. Yet it is one of the most evidence-supported interventions in gut medicine, and the 2022 and 2023 FDA approvals of the first standardized fecal microbiota products mark a genuine turning point in how medicine treats microbiome-related disease.

The challenge is that FMT’s strong results in C. diff have generated enormous enthusiasm for extending it to a wide range of other conditions, from Crohn’s disease to autism to depression. The evidence for those applications is far more complicated. The sections below cover what is known, what is still being studied, what the risks of getting ahead of the evidence look like, and how patients in Reno and elsewhere in the US actually reach the treatment.

What FMT Is and How the Procedure Works

FMT transfers the microbial community from a healthy donor’s stool into a recipient’s gastrointestinal tract. The goal is to displace a disrupted or pathogenic microbiome and restore a diverse community of bacteria, fungi, viruses and archaea. The human gut contains approximately 38 trillion microorganisms, and disruptions to this community, called dysbiosis, are linked to a growing list of conditions.

Clinicians now group these treatments as fecal microbiota-based therapies. That umbrella covers conventional FMT prepared from a single donor’s stool, standardized biologic products such as Rebyota and Vowst, and newer defined bacterial consortia still in trials. The procedure itself has several delivery options, each with different advantages depending on the target condition:

• Colonoscopic infusion delivers material directly to the colon. Lower GI delivery reached 95% resolution in the Quraishi meta-analysis, and colonoscopy was used in many C. diff trials.
• Enema delivery is lower tech and is used in some ulcerative colitis and C. diff protocols. Rebyota is given this way as a single 150 mL rectal dose.
• A nasogastric, nasoduodenal or nasojejunal tube delivers material to the upper GI tract. It is more practical for some patients but less preferred for colonic conditions.
• Oral capsules contain freeze-dried or purified material for swallowing. Vowst is taken as four capsules once a day for three consecutive days, according to the FDA (2023).

Donor stool undergoes rigorous screening before use in clinical settings. This includes testing for dozens of pathogens, extensive questionnaires about health history, medication use, travel and lifestyle, and in some programs an assessment of microbiome diversity. The largest US nonprofit stool bank has reported rejecting roughly 97% of prospective donors on these criteria.

C. difficile: Where FMT Has Proven Itself

Clostridioides difficile (C. diff) infection causes severe diarrhea, colitis and, in the worst cases, life-threatening toxic megacolon. Recurrent C. diff, where infection returns after antibiotic treatment, affects an estimated 150,000 to 200,000 Americans per year. The risk of another recurrence rises with each episode, which is why repeated courses of vancomycin or fidaxomicin often fail to break the cycle.

FMT for recurrent C. diff is one of the highest-response treatments in all of medicine. The landmark 2013 RCT by van Nood et al. in the New England Journal of Medicine (n=43) compared FMT via nasoduodenal tube with vancomycin antibiotic therapy. Infusion of donor feces resolved diarrhea in 81% of patients after one infusion and 94% after a second, versus 31% for vancomycin and 23% for vancomycin plus bowel lavage. The trial was stopped early after an interim analysis because the difference between the groups was so large.

Multiple subsequent RCTs and large case series have confirmed these results. A 2017 meta-analysis in Alimentary Pharmacology & Therapeutics (Quraishi et al.) analyzed 37 studies, 7 randomized trials and 30 case series, and found a pooled clinical resolution rate of 92% for FMT in recurrent and refractory C. diff. Fresh and frozen material performed about the same, at 92% and 93%. Evidence grade: Strong.

Who qualifies for FMT for C. diff?

Guidelines reserve FMT for recurrence, not a first infection. The American College of Gastroenterology guideline by Kelly et al. (2021) recommends FMT for patients experiencing their second or further recurrence of C. diff after appropriate antibiotic treatment. The AGA clinical practice guideline (Peery et al., 2024) suggests select use of fecal microbiota-based therapies in immunocompetent adults with recurrent C. diff once standard antibiotics are complete.

The same AGA guideline suggests conventional FMT for mildly or moderately immunocompromised adults with recurrent infection, and suggests against any fecal microbiota-based therapy in severely immunocompromised adults. It also suggests conventional FMT for select hospitalized adults with severe or fulminant C. diff that is not responding to antibiotics. A gastroenterologist or infectious disease physician makes that call after reviewing the full history.

FDA-Approved FMT Products: Vowst and Rebyota

The FDA’s approval of two standardized fecal microbiota products marks a fundamental shift from procedure to pharmaceutical product, with all the manufacturing standards and pharmacovigilance that implies. Both are regulated as biologics by the FDA’s Center for Biologics Evaluation and Research, and both carry a label warning that donated stool, even when tested, may transmit infectious agents.

Rebyota (RBX2660, fecal microbiota, live-jslm, by Ferring Pharmaceuticals) was approved on November 30, 2022 as a single-dose rectal suspension to prevent recurrence of C. diff in adults after antibiotic treatment. It is a microbiota suspension derived from screened donor stool and was the first fecal microbiota product the FDA approved. The pivotal PUNCH CD3 trial (n=267) showed a 70.6% success rate at 8 weeks versus 57.5% for placebo.

Vowst (SER-109, fecal microbiota spores, live-brpk, developed by Seres Therapeutics) was approved on April 26, 2023 as the first oral fecal microbiota product. It is made from purified spores of Firmicutes bacteria from screened donors. In the ECOSPOR III trial (Feuerstadt et al., 2022, NEJM, n=182), C. diff recurred within 8 weeks in 12% of the Vowst group versus 40% on placebo, a success rate of 88% versus 60%. Vowst’s oral route makes it more practical than colonoscopic FMT for many patients.

Investigational Uses: IBD, IBS, and Beyond

The success of FMT in C. diff has driven active investigation into a wide range of other conditions associated with gut microbiome dysbiosis. The evidence here is more complex, less consistent and, in most cases, not yet sufficient to support routine clinical use. The AGA (2024) suggests against conventional FMT for Crohn’s disease, ulcerative colitis, pouchitis and IBS outside clinical trials.

Ulcerative Colitis: Moderate Evidence

Ulcerative colitis (UC) is the inflammatory bowel disease with the most FMT trial data. Four published RCTs have examined FMT versus placebo for inducing remission in active UC. Results vary between trials but consistently show a benefit over sham treatment.

The FOCUS trial by Paramsothy et al. (2017, Lancet, n=81) used intensive multidonor FMT via colonoscopy followed by enemas 5 days per week for 8 weeks. The primary outcome, steroid-free remission with endoscopic improvement, was reached by 27% of the FMT group versus 8% in the placebo group. The trial by Moayyedi et al. (2015, Gastroenterology, n=75) gave weekly FMT enemas for 6 weeks and showed 24% remission in the FMT group versus 5% in controls at 7 weeks.

The variation in outcomes likely reflects differences in donor selection, delivery method, and treatment intensity. The field has moved toward identifying super-donors (individuals whose microbiome characteristics consistently produce good outcomes in recipients) as a key variable. In the Moayyedi trial, 7 of the 9 patients in remission had received stool from a single donor. Evidence grade: Moderate for UC, though not yet standard of care.

Crohn’s Disease: Emerging Evidence

The evidence for FMT in Crohn’s disease is less developed than for UC. Crohn’s involves the full thickness of the intestinal wall and can affect any part of the GI tract, making microbiome manipulation more complicated. Several small RCTs have produced inconsistent results. A 2020 pilot RCT in Microbiome (Sokol et al., n=17) tested a single colonoscopic FMT to maintain remission: no patient reached the primary endpoint, although steroid-free remission at 10 weeks was 87.5% (7 of 8) after FMT versus 44.4% (4 of 9) after sham. Larger trials are underway. Evidence grade: Emerging. Standard options are covered in the Crohn’s disease treatment guide.

Irritable Bowel Syndrome: Emerging but Conflicting Evidence

IBS trials have produced confusing results, partly because IBS is a heterogeneous condition with multiple subtypes and strong placebo responses. The trial by El-Salhy et al. (2020, Gut, n=165), using one well-characterized donor and delivery by gastroscope, found symptom response in 76.9% (30 g) and 89.1% (60 g) of patients versus 23.6% on placebo at 3 months. A later follow-up from the same group reported lasting effects at 3 years.

A well-designed trial by Halkjaer et al. (2018, Gut, n=52) using FMT capsules for 12 days found the opposite: the placebo group had greater symptom relief at 3 months. The inconsistency likely reflects differences in donor selection, dose, route and patient subgroups. Evidence grade: Emerging. People living with irritable bowel syndrome can compare established approaches in the IBS treatment guide.

Donor Screening: Why It Is Non-Negotiable

FMT’s safety record is generally good in regulated clinical settings, but the procedure has produced serious adverse events when donor screening was inadequate. In June 2019, the FDA issued a safety alert after two immunocompromised adults in a clinical trial developed invasive infections with extended-spectrum beta-lactamase (ESBL)-producing E. coli traced to the same donor. One patient died. The agency then required FMT donor stool to be tested for ESBL-producing organisms and other multidrug-resistant bacteria.

Proper donor screening includes blood tests for HIV, hepatitis B and C, syphilis and other blood-borne pathogens; stool tests for bacterial and parasitic pathogens, C. diff and antibiotic-resistant organisms; and detailed questionnaires about recent travel, antibiotic use, diet, medications and personal and family medical history. Large stool banks test each donor for dozens of potential pathogens and repeat testing at intervals, so a donor who passes once is not cleared indefinitely.

The Serious Risks of DIY FMT

A substantial underground community practices DIY FMT, using stool from friends or family members prepared at home and administered via enema. People turn to this route because clinical FMT for conditions other than C. diff is difficult to access, experimental and uninsured. The motivations are understandable. The risks are serious and underappreciated.

Even a donor who appears perfectly healthy can carry pathogens that are dangerous for a recipient. The 2019 ESBL case that led to a patient death involved a donor with no signs of illness, whose stool had not been tested for ESBL-producing organisms before use. Laboratory testing would have caught what appearances missed. Home preparation cannot replicate this level of safety assessment.

Beyond pathogen transmission, DIY FMT can transmit organisms associated with long-term health risks that are not yet fully characterized. There is theoretical concern about transmitting predispositions to metabolic syndrome, inflammatory conditions, or other microbiome-influenced diseases. The long-term consequences of altering the gut microbiome are still being understood even in carefully controlled clinical settings.

Who should not have FMT?

Severely immunocompromised adults, such as people with recent organ or stem cell transplants or on intensive chemotherapy, face the highest infection risk, and the AGA (2024) suggests against fecal microbiota-based therapy for recurrent C. diff in this group. People with a food allergy should know that donor material may contain food allergens, and anyone with a recent bowel perforation or severe colitis needs a specialist’s assessment of the delivery route first.

Accessing FMT in a Clinical Setting

For recurrent C. diff, Vowst and Rebyota are commercially available and increasingly covered by insurance, though coverage varies by plan and by whether the product is billed as a pharmacy or a medical benefit. Patients with recurrent C. diff should discuss these options with their gastroenterologist. Some academic medical centers also offer conventional FMT procedures under gastroenterology supervision.

For conditions outside of C. diff, FMT is available primarily through clinical trial enrollment. ClinicalTrials.gov lists dozens of active FMT trials for UC, Crohn’s, IBS and other conditions. Enrolling in a trial is the most appropriate way to access FMT for these indications, as it provides proper screening, monitoring and a contribution to the evidence base.

Fecal Transplant in Reno, NV: How to Find Care

Fecal transplant in Reno, Nevada follows the same medical pathway as anywhere else in the US. A patient with a second or later C. diff recurrence is referred by a primary care physician, hospitalist or urgent care clinician to a gastroenterologist or infectious disease specialist in Reno or Sparks. That specialist decides between Vowst, Rebyota and conventional FMT based on the patient’s history, immune status and insurance.

Vowst is taken at home after a short course of antibiotics and a bowel preparation, so a patient anywhere in Washoe County, Carson City or the Carson Valley along US 395 can complete it without repeat travel. Rebyota is given in a clinician’s office. Conventional colonoscopic FMT depends on a hospital endoscopy unit willing to source screened donor material, and some patients are referred to larger academic centers outside Nevada for it.

For IBS, ulcerative colitis or Crohn’s disease, search ClinicalTrials.gov for FMT studies by location and travel distance. Trials open and close often, and when none is enrolling in northern Nevada, Reno patients can look to sites in Northern California along the I-80 corridor or farther afield. A clinic that offers fecal transplants for these conditions outside a registered trial is working outside the guideline recommendations described above.

Questions to ask a Reno gastroenterologist about FMT

1. Does my C. diff history meet the ACG or AGA criteria for a fecal microbiota-based therapy?
2. Which option fits my case: Vowst, Rebyota or conventional FMT, and why?
3. How many days after my last antibiotic dose should treatment start?
4. Will my plan cover the product as a pharmacy or a medical benefit, and is prior authorization needed?
5. Who do I call if diarrhea returns in the 8 weeks after treatment?

How FMT Differs From Colon Hydrotherapy, Probiotics and SIBO Treatment

Fecal microbiota transplant adds a donor’s microbial community to the colon. Colon hydrotherapy, sometimes called colonic irrigation, flushes the colon with water and does not introduce donor microbes, so it is not a substitute for FMT and is not used to treat C. diff. A practice listed among colon hydrotherapy clinics offers an irrigation service, which is a different procedure from a microbiota transplant.

Over-the-counter probiotics contain a handful of strains at far lower diversity than donor stool, and evidence for them in recurrent C. diff is weak; the overview of gut health supplements covers what they can and cannot do. Small intestinal bacterial overgrowth is a different problem with its own diagnostic breath test and antibiotic or dietary protocols, described in the SIBO treatment guide and the comparison of IBS versus SIBO.

If you search the Regenerated.com directory for related gut health care, listing order is not paid ranking, and Featured slots are labeled and capped. Verified means a clinic completed credential checks, not that it spent money, and the directory is free for patients. Inclusion in a list is not an endorsement; the guide to Featured, Verified and organic listings explains each label.

Frequently asked questions

Can I get a fecal transplant in Reno, NV?

Yes, for recurrent C. diff. Reno gastroenterologists and infectious disease physicians can prescribe the FDA approved products Vowst, an oral capsule, and Rebyota, a rectal dose, after a second or later recurrence. Conventional colonoscopic FMT depends on a local endoscopy unit sourcing screened donor stool. For IBS, Crohn’s disease or ulcerative colitis, FMT is investigational, so the appropriate route is a registered clinical trial, which may mean traveling to Northern California or another state.

Is fecal transplant FDA approved?

Two fecal microbiota products are FDA approved, both only to prevent recurrence of C. diff infection in adults after antibiotic treatment. Rebyota, a rectal suspension, was approved in November 2022, and Vowst, an oral capsule made from purified bacterial spores, was approved in April 2023. Conventional FMT prepared from donor stool is not an approved product. The FDA allows its use for C. diff that has not responded to standard therapy, and other uses require trial oversight.

How successful is FMT for recurrent C. diff?

FMT resolves recurrent C. diff in most patients. A 2017 meta-analysis by Quraishi et al. pooled 37 studies and found clinical resolution in 92%. In the 2013 NEJM trial by van Nood et al., donor feces resolved infection in 94% of patients after up to two infusions, versus 31% with vancomycin alone. For the approved products, recurrence at 8 weeks was 12% with Vowst versus 40% with placebo, and success was 70.6% with Rebyota versus 57.5% with placebo.

Does FMT work for IBS or ulcerative colitis?

The evidence is mixed, and FMT is not standard care for either condition. In ulcerative colitis, trials such as FOCUS (Paramsothy et al., 2017) found remission in 24% to 27% of FMT patients versus 5% to 8% on placebo. IBS trials conflict: El-Salhy et al. (2020) reported strong responses, while Halkjaer et al. (2018) found placebo did better. The AGA (2024) suggests against FMT for IBS and inflammatory bowel disease except in clinical trials.

Is it safe to do a fecal transplant at home?

Home or DIY fecal transplants carry real risks that clinical programs exist to prevent. A healthy-looking donor can carry drug-resistant bacteria, parasites or viruses that only laboratory testing detects. In 2019, the FDA reported that two immunocompromised patients developed ESBL-producing E. coli infections from one donor’s stool and one died. Home preparation also offers no dosing control or medical follow-up. Patients with recurrent C. diff have approved options through a gastroenterologist instead.

Is FMT the same as colon hydrotherapy?

No. FMT introduces a screened donor’s gut microbes into the colon or upper GI tract to rebuild a damaged microbiome, and it is prescribed by gastroenterologists and infectious disease physicians. Colon hydrotherapy irrigates the colon with water and adds no donor microbes. It is not used for C. diff and is not a form of fecal transplant. A clinic that offers colonics is not offering FMT unless it says so explicitly and works under physician and FDA oversight.

The Bottom Line

FMT is one of the most transformative treatments in gastroenterology. For recurrent C. difficile, the evidence is overwhelming, and two FDA approved products, Rebyota and Vowst, now make it accessible as a conventional prescription, including for patients in Reno and across northern Nevada. For IBD and IBS, the biology is compelling and some early trial data is promising, but the inconsistency of results means it is not ready for broad clinical use outside of research settings.

The microbiome field is moving quickly. The approval of Vowst and Rebyota signals that pharmaceutical-grade microbiome products are a viable category, and several additional products are in development for UC and other conditions. Phase III trial results over the next few years will clarify which indications join C. diff as validated FMT applications. For now, the evidence points one way: use FMT for recurrent C. diff, where it works extraordinarily well, and join a registered trial for other conditions rather than pursuing unregulated alternatives.